mynth
← DATABASE
02/2025100%

Feed Enzyme Alliance acquired by Novonesis

DENMARK Life Sciences / Animal Health EV €1–10bn

Context

This transaction is a strategic corporate carve-out and vertical integration wherein Novonesis fully acquires the sales and distribution activities of the Feed Enzyme Alliance from its long-term joint venture partner, dsm-firmenich. Supported by a fully committed debt financing package, this operation effectively dissolves the historical alliance, granting Novonesis absolute control over the entire commercial value chain. The primary strategic rationale underpinning this acquisition is to directly combine the acquirer's established innovation and production capabilities with the target's extensive global go-to-market network. This powerful consolidation will significantly accelerate Novonesis's market penetration, unlock substantial revenue synergies, and solidify its undisputed leadership position within the global animal nutrition and biosolutions industry.

Feed Enzyme Alliance, which reported an EBITDA margin of [members only] in 2025, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.

-> Deep-dive in Healthcare & Pharma market trends

Target

The Feed Enzyme Alliance was a 25-year joint venture focused on the development, production, and distribution of enzymes for animal nutrition. By delivering highly innovative, sustainable nutritional solutions and market-leading feed enzymes, the enterprise serves a broad, diverse customer base across the global animal nutrition and health sectors. Its robust commercial operations provide deep insights into core markets, fostering continuous technological innovation and sustainable value creation within the agricultural supply chain.

Ent. Value

€1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

15x–25x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2025
[members only]
€50–100M
[members only]
2024
[members only]
€50–100M
[members only]

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
03/2025LBO FRANCEHEMODIAFRANCEMedical Devices
03/2025NUTRISENSPRODIETBRAZILNutrition & Dietary Supplements
02/2025EURAZEO / TURENNE CAPITAL / KURMA PARTNERSGERMITECFRANCEMedical Devices
01/2025QUADRIVIO GROUPMIR - MEDICAL INTERNATIONAL RESEARCHITALYDiagnostic Equipment
01/2025ANIMALCARE GROUPRANDLABAUSTRALIAAnimal Health
12/2024NEXTSTAGE / IK PARTNERSEUROBIO SCIENTIFICFRANCEDiagnostic Equipment
12/2024GOLDMAN SACHSSYNTHON INTERNATIONALNETHERLANDSGenerics / Labs
12/2024UI INVESTISSEMENTDIDACTICFRANCEMedical Consumables
11/2024NAXICAP PARTNERSGLOBAL DFRANCEImplants & Prosthetics
10/2024BANSK GROUPPETIQUNITED STATESAnimal Health

REFERENCES

Valuation range: EV €1–10bn

EBITDA range: €50–100M

EV/EBITDA range: 15x - 25x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Feed Enzyme Alliance by Novonesis are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers Novonesis’s acquisition of 100% of Feed Enzyme Alliance, a Danish company specialised in Animal Health, in 2025.

How was the acquisition of Feed Enzyme Alliance by Novonesis valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €1–10bn band and its EV/EBITDA multiple within the 15x - 25x range. Exact figures are available to members.

What was Feed Enzyme Alliance’s EBITDA at the time of the deal?

At the time of the transaction, Feed Enzyme Alliance’s EBITDA was estimated within the €50–100M bracket (FY 2025). Detailed financial figures are available to members.

What sources support the information on this transaction?

The details of this transaction are sourced directly from the official corporate announcement published on the parties’ institutional website, ensuring primary-source verification of the closing and perimeter.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.